PHILADELPHIA — A new 10-day treatment regimen with the oral potassium-competitive acid blocker vonoprazan, and the antibiotics levofloxacin and amoxicillin, was significantly more effective at eradicating Helicobacter pylori infection than triple therapy with omeprazole, amoxicillin, and clarithromycin, according to the results of a randomized, multicenter study.
In addition, the triple therapy regimen with vonoprazan was generally better tolerated than the 14-day omeprazole-based regimen.
The new treatment combination was created to tackle the two main reasons that patients with H pylori experience treatment failure: Inadequate acid suppressant activity and antibiotic resistance, said principal investigator Kachonsak Yongwatana, MD, from Phramongkutklao Hospital in Bangkok, Thailand.
“Vonoprazan” is the more potent option for acid suppression, and “levofloxacin” addresses antibiotic resistance, he explained.
Yongwatana presented the findings (Abstract 41) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. The ACG recently released a clinical guideline on the treatment of H pylori infection.
Robust Eradication Rates
Yongwatana and colleagues enrolled adult patients with H pylori infections at four hospitals in Thailand between December 2022 and September 2023. The presence of H pylori was confirmed by upper gastrointestinal endoscopy with positive rapid urease test or positive test on tissue biopsy.
Patients were then randomized into two treatment groups: The 10-day VAL group (vonoprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, and levofloxacin 500 mg once daily for 10 days) and the 14-day OAC group (omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 14 days). Eradication was assessed by urea breath test 4 weeks after completion of treatment.
There were 280 patients in total, ie 140 in each group. There were no significant differences in baseline characteristics between the groups. The most common endoscopic findings among all participants included erosive gastritis (38%), nonerosive gastritis (27%), and gastric ulcer (17%).
In comparing the treatments, the researchers found that 10-day VAL led to significantly greater H pylori eradication rate than the 14-day OAC group in both intention-to-treat analysis (91.4 % vs 80.7%, P = .009) and per-protocol analysis (93.4% vs 83.7%, P = .012).
Vonoprazan-based therapy was also well tolerated by participants. Patients in the 10-day VAL group had significantly lower rates of experiencing a bitter taste (2.1% vs 42.9%, P P = .033) than those in the 14-day OAC group.
Isolating the BMI Effect
The researchers conducted a subgroup analysis on potential factors influencing response, which revealed that having a body mass index (BMI) H pylori eradication (relative risk [RR], 2.27; P = .049).
They then analyzed whether this BMI threshold was predictive in the separate treatment regimens. Although having a BMI P = .026), no such effect was noted in the 10-day VAL group (RR, 1.10; P = .888).
The influence of BMI could be due to the bioavailability of the treatments used in the regimen, Younwatana told Medscape Medical News. He and his colleagues recommended against using the 14-day OAC regimen in those with BMI ≥ 23.5.
“In patients with a high BMI, we should be concerned that normal proton-pump inhibitors may not work,” he said. “You have to step up to the higher-potency options.”
Seeking Confirmation in Other Populations
Session co-moderator Felice Schnoll-Sussman, MD, MSc, FACG, professor of clinical medicine and the director of the Jay Monahan Center for Gastrointestinal Health, director of the DIGEST program, and the associate chair of medicine for Outreach and Network at New York-Presbyterian Brooklyn Methodist Hospital in New York City, told Medscape Medical News that the promising results merit confirmation in other populations.
“When you see a study that is coming out of one country, when there could be issues related to antibiotic sensitivity in H pylori, it really is important to decide whether or not this is applicable to other patient populations,” said Schnoll-Sussman, who was not involved in the study.
She noted that this is also true of the findings from the subgroup as it is unclear whether average rates of BMI are notably lower in Thailand from other countries.
“As we know, BMI affects so many things with disease states. So, it’s a possibility in a country where the BMI is actually lower, there may be something else about these individuals in terms of their wellness status that could be underlying the effect.”
The study had no specific funding, although Takeda supplied treatments used in the analysis. Yongwatana reported no relevant financial relationships. Schnoll-Sussman reported serving as an advisory committee/board member for Braintree, Ethicon, Implantica, and Phathom.
John Watson is a freelance writer in Philadelphia, Pennsylvania.
Source link : https://www.medscape.com/viewarticle/shorter-h-pylori-treatment-vonoprazan-shows-better-results-2024a1000k2r?src=rss
Author :
Publish date : 2024-11-04 10:44:55
Copyright for syndicated content belongs to the linked Source.